ScreenerHero
COLLCollegium Pharmaceutical, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · collegiumpharma.com
27.29USD-5.05%Mkt Cap: 890.92M $P/E: 22.63

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap890.92M $
Enterprise Value1.98B $
Revenue (TTM)808.21M $
Gross Profit463.26M $
Net Income (TTM)62.87M $
Revenue/Share25.30 USD
Last Price27.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees423
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS19459J1043
Valuation
P/E (Trailing)22.63
P/E (Forward)4.07
PEG—
EV/EBITDA4.90
EV/Revenue2.46
P/S1.06
P/B2.87
EPS (TTM)1.21
EPS (Forward)6.77
52W Range
25.477% of range50.79
52W High50.79 USD
52W Low25.47 USD
Profitability
Gross Margin59.35%
Oper. Margin5.65%
EBITDA Margin50.14%
Profit Margin8.05%
ROE20.84%
ROA3.79%
Growth
Revenue Growth6.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF329.32M $
CapEx (TTM)1.74M $
FCF Margin40.09%
FCF Yield36.37%
Net Debt1.09B $
Net Debt/EBITDA2.69
Balance Sheet
Debt/Equity2.70
Current Ratio1.03
Quick Ratio0.70
Book Value/Sh9.598 USD
Cash/Share3.977 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.60 USD
Upside (mean)+81.8%
Target Range43.00 USD – 60.00 USD
$43.00+81.8% to mean$60.00
# Analysts5
Ownership
Shares Out.31.00M
Float32.17M
Insiders1.15%
Institutions127.59%
Short Interest
Short Ratio13.6d
Short % Float18.73%
Short % Out.15.66%
Shares Short5.08M
Short (prev mo.)5.47M
Technical
SMA 5033.79 (-19.2%)
SMA 20038.97 (-30.0%)
Beta0.76
S&P 52W Chg18.16%
Avg Vol (30d)562.16K
Avg Vol (10d)962.67K
Technical Indicators
RSI (14)37.0
MACD-2.0784
MACD Signal-1.6217
MACD Hist.-0.4568
BB Upper40.23 USD
BB Middle32.11 USD
BB Lower24.00 USD
BB Width50.57%
ATR (14)1.714 USD
Vol Ratio (20d)1.18x